Quest Diagnostics Incorporated · NYSE:DGX
Quest Diagnostics — Investor Day (March 2025)
17 slides from Quest Diagnostics's investor day presentation, Mar 19, 2025
Slide 1: Diagnostic Innovation as a Growth Driver
Diagnostic Innovation as a Growth Driver Karthik Kuppusamy, PhD Senior Vice President, Clinical Solutions
Slide 2: Safe harbor disclosure
Safe harbor disclosure The statements in this presentation which are not historical facts may be forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management's current esti
Slide 3: Key highlights
We are committed to delivering the most comprehensive portfolio of diagnostic lab innovation We expect to deliver double-digit revenue growth in advanced diagnostics across 5 key clinical areas Key highlights We are well positioned to grow revenues for Haystack MRD , building on our leadership in on
Slide 4: We deliver diagnostic innovation across the continuum of care
We deliver diagnostic innovation across the continuum of care to offer comprehensive, scaled solutions Risk Periodic Disease Disease Therapy Therapy Follow-up evaluation screening diagnosis prognosis selection monitoring care What is my What Is it possible Am I sure I What therapy Is my risk of dire
Slide 5: Advanced Diagnostics in 5 key clinical areas to deliver double-digit growth
Advanced Diagnostics We expect new and existing advanced diagnostic tests in 5 key clinical areas to deliver double-digit growth Oncology Advanced Women’s & Brain Autoimmune Cardiometabolic Reproductive Health Disorders Health Health • Haystack MRD • ApoB • QNatal® Advanced • AD-Detect ® • ANAlyzeR
Slide 6: We develop our own lab innovations and partner/buy to source others
We develop our own lab innovations and partner/buy to source others 1 2 3 4 5 Leverage IVD Develop organic License and create Partnerships Acquire new suppliers’ innovations via innovation from that leverage capabilities to innovation Quest R&D third-party IP our scale extend portfolio ELF Liver Fib
Slide 7: Panel discussion
Panel discussion Diagnostic innovation as a growth driver Yuri Fesko, MD, Senior Vice President and Chief Medical Officer Dan Edelstein, Vice President and General Manager, Haystack MRD Mouris Saghir, PhD, Vice President and General Manager, Cardiometabolic, Endocrine, and Wellness Kathleen Valentin
Slide 8: Advanced cardiometabolic solutions focus on prevention via early identification
Our advanced cardiometabolic solutions focus on prevention via early identification 1 in 3 ~128M Americans ~38M have type 2 36M have chronic Americans have metabolic-associated Only 7% of the population have heart steatotic liver disease diabetes kidney disease (CKD) disease (MASLD) has normal metab
Slide 9: Sensitive MRD test will optimize patient management with early detection
With 18+ million patients treated for cancer in the US, our sensitive MRD test will optimize patient management with early detection Surgery Adjuvant therapy Additional therapy “Is adjuvant therapy successful?” “Did we surgically “Is the cancer remove all the cancer?” coming back?” Whole-exome Resid
Slide 10: Differentiated solutions across each stage of a woman's life
Delivering differentiated solutions across each stage of a woman’s life Routine, guideline- Symptomatic Pregnancy/ based screenings solutions reproductive health during well-woman visits to help diagnose and treat for every step of the reproductive journey • Cervical cancer – Hologic Genius • STIs:
Slide 11: Quest AD-Detect blood testing helps assess risk of Alzheimer's disease
Quest AD-Detect blood testing helps assess risk of Alzheimer’s disease in early stages 12% - 18% of people age 60 or older are living with mild cognitive impairment... a possible sign of Alzheimer's disease New AD-Detect Abnormal Amyloid beta panel combines P-Tau amyloid beta Brain changes Memory an
Slide 12: Personalize diagnosis, treatment, and care for autoimmune disorders
We help providers personalize diagnosis, treatment, and care for their patients with autoimmune disorders Autoimmune disease ~24M Americans Screening/diagnosis Therapy selection Disease monitoring 100+ different types Features ANAlyzeR Personalized medicine for Serological testing to Autoimmune Scre
Slide 13: Haystack MRD leverages Quest's strengths and scale to broaden access
Haystack MRD leverages Quest’s unique strengths and scale to broaden access Blood testing at scale Streamlined access • ~8,000 patient access to biopsy tissue sites for blood draws • 400+ pathologists • ~10k tissue $1B specimens/day annual oncology Comprehensiveness revenues National connectivity of
Slide 14: We are challenging the existing hypothesis of cardiovascular disease
We are challenging the existing hypothesis of cardiovascular disease Cardiovascular mortality trends* Assay to measure Existing However Emerging HDL function hypothesis 135 500 science 130 480 Cardiovascular mortality 460 125 Normal lipid Normal lipid Avg LDL-C (mg/dL) 440 (in Thousands) 120 levels
Slide 15: Developing novel solutions for preeclampsia
Developing novel solutions for preeclampsia Potentially life-threatening hypertensive disorder during pregnancy Disrupt Diagnosis Prevalence~5.5M Acute increase in blood pregnancies in pressure AND US each year • Proteinuria OR • Thrombocytopenia • Impaired renal function • Impaired liver function ~
Slide 16: We are empowering earlier diagnosis and prevention
We are empowering earlier diagnosis and prevention • We are delivering diagnostic lab services that address unmet clinical needs affecting large patient populations • We are driving innovation to deliver earlier, more precise health insights—empowering clinicians with confidence to act sooner • Thro
Slide 17: Key takeaways
We are committed to delivering the most comprehensive portfolio of diagnostic lab innovation We expect to deliver double-digit revenue growth in advanced diagnostics across 5 key clinical areas Key takeaways We are well positioned to grow revenues for Haystack MRD , building on our leadership in onc